Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) hit a new 52-week low during trading on Wednesday after UBS Group lowered their price target on the stock from $117.00 to $113.00. UBS Group currently has a neutral rating on the stock. Jazz Pharmaceuticals traded as low as $102.86 and last traded at $103.53, with a volume of 304466 shares. The stock had previously closed at $105.09.
Several other research analysts also recently commented on JAZZ. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Truist Financial restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Needham & Company LLC cut their price target on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a report on Thursday, June 20th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Finally, StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 27th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $188.62.
Insider Activity
In related news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at $4,016,369.85. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Jazz Pharmaceuticals
Several institutional investors have recently modified their holdings of JAZZ. Capital World Investors acquired a new stake in Jazz Pharmaceuticals during the 1st quarter worth $171,943,000. Vestal Point Capital LP acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $89,175,000. Armistice Capital LLC raised its position in shares of Jazz Pharmaceuticals by 108.4% during the fourth quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock worth $80,150,000 after purchasing an additional 338,882 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after purchasing an additional 224,865 shares in the last quarter. Finally, Perpetual Ltd grew its position in shares of Jazz Pharmaceuticals by 54.0% in the 1st quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company’s stock valued at $57,202,000 after purchasing an additional 166,543 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.
Jazz Pharmaceuticals Trading Down 1.5 %
The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $6.53 billion, a P/E ratio of 21.35, a PEG ratio of 1.64 and a beta of 0.58. The business has a 50 day moving average of $108.80 and a 200-day moving average of $116.44.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The company had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.